## **Core Concept**
The use of combined oral contraceptives (COCs) is associated with various risks and benefits. COCs contain both estrogen and progestin, which can affect multiple physiological systems. One of the risks associated with COCs is an increased risk of certain types of thrombosis.

## **Why the Correct Answer is Right**
The correct answer, **Venous Thromboembolism (VTE)**, is right because COCs are known to increase the risk of VTE, which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). This risk is attributed to the estrogen component of COCs, which can enhance the coagulability of blood by increasing the production of clotting factors and decreasing the production of anticoagulant proteins. The progestin component can also contribute to this risk, although the effect is generally less pronounced than that of estrogen.

## **Why Each Wrong Option is Incorrect**
- **Option A: Myocardial Infarction** - While COCs can increase the risk of arterial thrombosis, including myocardial infarction, especially in smokers or those with other cardiovascular risk factors, the most directly and significantly increased risk is that of venous thromboembolism.
- **Option B: Breast Cancer** - There is a complex relationship between COCs and breast cancer risk. Some studies suggest a slightly increased risk of breast cancer in current and recent users of COCs, but this risk appears to decrease over time after stopping COCs and returns to baseline within a few years.
- **Option C: Ovarian Cancer** - COCs actually decrease the risk of ovarian cancer. The longer COCs are used, the greater the reduction in risk, which persists for many years after stopping.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the risk of venous thromboembolism is highest in the first year of COC use, particularly in the first 3-6 months. It's crucial for clinicians to assess the risk factors for VTE in patients starting COCs, such as smoking status, age, and personal or family history of thrombosis.

## **Correct Answer: D. Venous Thromboembolism**